New drug combo aims to boost Cancer-Killing power of radiation
NCT ID NCT06440850
Summary
This study is testing whether taking two oral drugs (vemurafenib and cobimetinib) before standard radioactive iodine treatment can improve outcomes for patients with high-risk thyroid cancer that has a specific genetic change (BRAFV600E mutation). The goal is to see if these drugs can make the cancer cells more responsive to the radiation. The trial will enroll about 21 adults who have not yet received radioactive iodine treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID GLAND PAPILLARY CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.